TCBP

TC BioPharm (Holdings) plc [TCBP] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

TCBP Stock Summary

Top 10 Correlated ETFs

TCBP


Top 10 Correlated Stocks

TCBP


In the News

12:47 26 Feb 2024 TCBP

TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug

The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.

08:30 26 Feb 2024 TCBP

TC BioPharm to Present at H.C. Wainwright 25th Annual Global Investment Conference

EDINBURGH, Scotland , Aug. 29, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, September 11 th through Wednesday, September 13 th starting at 7:00 a.m.

01:48 26 Feb 2024 TCBP

3 Hot Penny Stocks To Watch After TUP Stock Explodes, Again

Why would anyone want to buy penny stocks? They're extremely risky.

03:06 26 Feb 2024 TCBP

Penny Stocks to Watch: Why Is ELOX Stock Skyrocketing?

Most traders dream of hitting it big, and penny stocks are some of the most attractive for day traders. It can be any given session where we see at least a handful of cheap stocks under $5 explode.

08:00 26 Feb 2024 TCBP

TC BioPharm to Present at the Sequire Investor Summit in Puerto Rico

EDINBURGH, Scotland, April 19, 2023 (GLOBE NEWSWIRE) -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is proud to announce its participation at the upcoming Sequire Investor Summit. This highly anticipated event, scheduled for April 24-26, 2023 at La Concha Resort in San Juan, Puerto Rico, promises to offer an array of exciting opportunities for funds, companies, and investors.

11:51 26 Feb 2024 TCBP

Why Are TC Biopharm Shares Trading Higher Today

The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ: TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia.  After reviewing the Phase 1b/2a trial results in relapsed/refractory AML patients, the FDA approved the Company's application.

09:23 26 Feb 2024 TCBP

Trading Penny Stocks? Top Stock Market News for March 9th, 2022

Here's what you need to know about trading penny stocks on March 9th The post Trading Penny Stocks? Top Stock Market News for March 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

03:18 26 Feb 2024 TCBP

Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February

Here's three penny stocks that investors are watching rig The post Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February   appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

02:11 26 Feb 2024 TCBP

U.S. IPO Weekly Recap: 3 Micro-Cap IPOs Come To Market During The February Lull

The Arena Group, a media holding company operating Sports Illustrated, TheStreet, and other brands, raised $30 million at a $172 million market cap. Nine SPACs went public this past week.

12:43 26 Feb 2024 TCBP

5 ‘Must Watch' Penny Stocks For February 2022

5 must watch penny stocks that you should know about in February The post 5 ‘Must Watch' Penny Stocks For February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

TCBP Financial details

Company Rating
Buy
Market Cap
31.73K
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
60
Optionable
No
Shortable
Yes
Earnings
12 Dec 2022
P/E
-0.87
Forward P/E
-
PEG
-
P/S
0.31
P/B
-47.09
P/C
-
P/FCF
-0.08
Quick Ratio
0.72
Current Ratio
0.81
Debt / Equity
1.16
LT Debt / Equity
0.83
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
1.58
EPS this Y
-94.18%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-44.49%
-
-
-
-
SMA20
-46.12%
SMA50
-82.87%
SMA100
-98.63%
Inst Own
10.82%
Inst Trans
1.12%
ROA
-13%
ROE
17%
ROC
-6.75%
Gross Margin
100%
Oper. Margin
-314%
Profit Margin
-36%
Payout
-
Shs Outstand
30.22K
Shs Float
4.6M
-
-
-
-
Target Price
-
52W Range
0.85-907.0
52W High
-
52W Low
-
RSI
33.66
Rel Volume
0.56
Avg Volume
785.61K
Volume
437.18K
Perf Week
-13.22%
Perf Month
-53.54%
Perf Quarter
-99.06%
Perf Half Y
-99.02%
-
-
-
-
Beta
0.044
-
-
Volatility
0.06%, 0.54%
Prev Close
-13.93%
Price
1.05
Change
-3.67%

TCBP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
6.113.535.065.59
Net income per share
-10.81-9.73-34.73-2.02
Operating cash flow per share
-11.99-6.12-14.28-21.14
Free cash flow per share
-15.91-6.48-14.64-21.68
Cash per share
1.71.334.017
Book value per share
-4.53-5.96-42.36-0.04
Tangible book value per share
-5.07-6.72-43.59-0.84
Share holders equity per share
-4.53-5.96-42.36-0.04
Interest debt per share
6.625.9133.6314.24
Market cap
9.01B8.73B6.14B437.34M
Enterprise value
9.01B8.73B6.15B435.33M
P/E ratio
-1.48K-1.6K-452.28-314.7
Price to sales ratio
2.63K4.41K3.1K113.76
POCF ratio
-1.34K-2.54K-1.1K-30.1
PFCF ratio
-1.01K-2.4K-1.07K-29.36
P/B Ratio
-3.55K-2.61K-370.8-17.03K
PTB ratio
-3.55K-2.61K-370.8-17.03K
EV to sales
2.63K4.41K3.11K113.23
Enterprise value over EBITDA
-1.58K-1.66K-982.85-39.24
EV to operating cash flow
-1.34K-2.54K-1.1K-29.96
EV to free cash flow
-1.01K-2.4K-1.07K-29.23
Earnings yield
0000
Free cash flow yield
000-0.03
Debt to equity
-1.35-0.9-0.59-108.81
Debt to assets
0.340.421.210.26
Net debt to EBITDA
-0.43-0.43-1.30.18
Current ratio
1.090.530.190.81
Interest coverage
-24.03-21.7-2.12-1.72
Income quality
0.980.520.374.67
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0.881.121.572.16
Research and developement to revenue
2.513.383.111.94
Intangibles to total assets
0.030.060.060.05
Capex to operating cash flow
0.330.060.030.03
Capex to revenue
-0.64-0.1-0.07-0.09
Capex to depreciation
-2.43-0.19-0.14-0.38
Stock based compensation to revenue
0.240.4100.29
Graham number
33.1836.13181.921.3
ROIC
-1.34-1.931.67-1.1
Return on tangible assets
-0.62-0.8-1.8-0.13
Graham Net
-16.85-15.93-56.04-7.01
Working capital
335.78K-1.97M-16.72M-1.72M
Tangible asset value
-2.85M-3.77M-17.04M-578.69K
Net current asset value
-8.46M-8.4M-20.73M-3.53M
Invested capital
-1.35-0.9-0.59-108.81
Average receivables
02.13M1.36M1.64M
Average payables
0633.15K1.03M1.15M
Average inventory
0000
Days sales outstanding
321.78228.43272.62171.21
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
1.131.61.342.13
Payables turnover
0000
Inventory turnover
0000
ROE
2.391.630.8254.12
Capex per share
-3.91-0.37-0.37-0.53

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2021-12-312022-06-302022-11-102022-12-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
1.270000
Net income per share
-9.980000
Operating cash flow per share
-6.510000
Free cash flow per share
-6.650000
Cash per share
4.010000
Book value per share
-42.360000
Tangible book value per share
-43.590000
Share holders equity per share
-42.360000
Interest debt per share
29.750000
Market cap
6.14B0000
Enterprise value
6.15B-2.59M0-2.01M408.86K
P/E ratio
-393.580000
Price to sales ratio
12.41K0000
POCF ratio
-2.41K0000
PFCF ratio
-2.36K0000
P/B Ratio
-370.80000
PTB ratio
-370.80000
EV to sales
12.43K0000
Enterprise value over EBITDA
-2.96K0000
EV to operating cash flow
-2.41K0000
EV to free cash flow
-2.37K0000
Earnings yield
00000
Free cash flow yield
00000
Debt to equity
-0.593.350-108.811.16
Debt to assets
1.210.2500.260.28
Net debt to EBITDA
-3.920000
Current ratio
0.191.1300.811.09
Interest coverage
-1.210000
Income quality
0.560000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
2.380000
Research and developement to revenue
3.330000
Intangibles to total assets
0.060.0400.050.07
Capex to operating cash flow
0.020000
Capex to revenue
-0.110000
Capex to depreciation
-0.210000
Stock based compensation to revenue
00000
Graham number
97.50000
ROIC
0.510000
Return on tangible assets
-0.520000
Graham Net
-56.040000
Working capital
-16.72M1.1M0-1.72M390.07K
Tangible asset value
-17.04M498.35K0-578.69K1.41M
Net current asset value
-20.73M-2.73M0-3.53M-1.27M
Invested capital
-0.593.350-108.811.16
Average receivables
1.18M01.14M901.66K0
Average payables
1.4M0844.69K441.18K0
Average inventory
00000
Days sales outstanding
268.880000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.330000
Payables turnover
00000
Inventory turnover
00000
ROE
0.240000
Capex per share
-0.130000

TCBP Frequently Asked Questions

What is TC BioPharm (Holdings) plc stock symbol ?

TC BioPharm (Holdings) plc is a GB stock and trading under the symbol TCBP

What is TC BioPharm (Holdings) plc stock quote today ?

TC BioPharm (Holdings) plc stock price is $1.05 today.

Is TC BioPharm (Holdings) plc stock public?

Yes, TC BioPharm (Holdings) plc is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap